# Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

> **NCT00959946** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Advanced Breast Cancer (Parts 1 and 2)
- Advanced Pancreatic Cancer (Part 1)
- Advanced Colorectal Cancer (Part 1)
- Advanced Cholangiocarcinoma (Part 1)
- Advanced Glioblastoma Multiforme (Part 1)

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00959946
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959946, "Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00959946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*